Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.586 USD | -3.46% |
|
+2.81% | -92.34% |
05-21 | FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD | CI |
05-08 | Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Equities
- CING Stock
- Revisions Cingulate Inc.